Wes Wheeler/Tim Arendt-Twin Destroyers??
- Thread starter Anonymous
- Start date
-
- Tags
- None
Yes, it is where Simon Jose, a Brit of Indian ethnicity, works along with other senior leaders
Extreme weight loss have just signed a new season with Marken executives!!! Who will be the winner ?
Check latest LinkedIn post
Check latest LinkedIn post
Breaking News :
http://mobile.reuters.com/article/idUSKCN0ZH5P6
TOP NEWS
Fri Jul 1, 2016 | 2:31 PM EDT
Medical courier Marken up for sale:
By Carl O'Donnell and Lauren Hirsch
(Reuters) - Privately held U.S. cold-storage medical shipper Marken is exploring a sale that could value it at more than $1 billion, including debt, according to people familiar with the matter.
The move illustrates how a pickup in demand for outsourced pharmaceutical services and drug shipping has reversed the fortunes of a company that previously struggled with fierce competition from other logistics groups and lower levels of research and development spending by drug makers.
Marken, which ships vaccines and blood from clinical trials around the world, is working with investment bank UBS Group AG on an auction process, the people said this week.
The company, which has 12-month earnings before interest, taxes, depreciation and amortization of around $100 million, could attract interest from large logistics companies such as United Parcel Service Inc and FedEx Corp, as well as private equity firms, the sources said.
The process is still in its early stages and no deal may be reached, the people added, asking not to be identified because the sale process is confidential.
ADVERTISEMENT
Marken, United Parcel Service and FedEx did not respond to requests for comment. UBS declined to comment.
Marken was taken over four years ago by a consortium of lenders who helped finance the acquisition of the company in 2009 by Apax Partners LLP for 1 billion pounds ($1.32 billion). Apax lost its 600 million pound investment in the financial restructuring.
Since then, specialty pharmacies and distributors have benefited from a wave of innovative new drugs that often require complex handling, including prominent new treatments that can cure Hepatitis C.
At the same time, life sciences companies have increasingly outsourced research spending to contractors, creating more opportunities for firms like Marken.
Marken, which is based in Durham, North Carolina and Chiswick, England, has expertise in distributing products that are highly sensitive to temperature, including products that need to be stored at below minus 100 degrees Fahrenheit.
http://mobile.reuters.com/article/idUSKCN0ZH5P6
TOP NEWS
Fri Jul 1, 2016 | 2:31 PM EDT
Medical courier Marken up for sale:
By Carl O'Donnell and Lauren Hirsch
(Reuters) - Privately held U.S. cold-storage medical shipper Marken is exploring a sale that could value it at more than $1 billion, including debt, according to people familiar with the matter.
The move illustrates how a pickup in demand for outsourced pharmaceutical services and drug shipping has reversed the fortunes of a company that previously struggled with fierce competition from other logistics groups and lower levels of research and development spending by drug makers.
Marken, which ships vaccines and blood from clinical trials around the world, is working with investment bank UBS Group AG on an auction process, the people said this week.
The company, which has 12-month earnings before interest, taxes, depreciation and amortization of around $100 million, could attract interest from large logistics companies such as United Parcel Service Inc and FedEx Corp, as well as private equity firms, the sources said.
The process is still in its early stages and no deal may be reached, the people added, asking not to be identified because the sale process is confidential.
ADVERTISEMENT
Marken, United Parcel Service and FedEx did not respond to requests for comment. UBS declined to comment.
Marken was taken over four years ago by a consortium of lenders who helped finance the acquisition of the company in 2009 by Apax Partners LLP for 1 billion pounds ($1.32 billion). Apax lost its 600 million pound investment in the financial restructuring.
Since then, specialty pharmacies and distributors have benefited from a wave of innovative new drugs that often require complex handling, including prominent new treatments that can cure Hepatitis C.
At the same time, life sciences companies have increasingly outsourced research spending to contractors, creating more opportunities for firms like Marken.
Marken, which is based in Durham, North Carolina and Chiswick, England, has expertise in distributing products that are highly sensitive to temperature, including products that need to be stored at below minus 100 degrees Fahrenheit.
1 billion? That is to be seen.
Wes (big ego) wheeler unrealistic as usual.
WC was sold for less than half a million a couple of years ago and the an Apax's like debacle is very unlikely to happen again.
As of now Marken is destined to disappear.
Wes (big ego) wheeler unrealistic as usual.
WC was sold for less than half a million a couple of years ago and the an Apax's like debacle is very unlikely to happen again.
As of now Marken is destined to disappear.
Contrary to portrayal it would seem that he did idealize his predecessors, wanting sell for 1 billion. Memories of Dr evil.
The company have always sold at a profit.
Anything less than the last sale will be a failure.
A failure will be then, because they are losing costumers like Icon which is gone at a fast pace.
Good luck finding a buyer for at least half if not less of the presuntuoos asking price.
Good luck finding a buyer for at least half if not less of the presuntuoos asking price.
These two have been mentioned so much that it seems as if the poster was fired . Get a life please and move on. Your sales skill level was very low evidently. Hope you found a better job.
The party is over. The firings will begin soon. The ax is swinging.
UPS acquires pharmaceutical logistics specialist Marken
Delivery giant continues expansion into lucrative sector of global clinical trials shipments.
By Ben Ames
0 Comments
UPS said the deal is expected to close by Dec. 31.
Atlanta-based UPS has been investing heavily in the specialized services it needs to claim a larger share of this lucrative market. In July, the company announced that it would expand its ability to provide temperature control, precision parcel tracking, and other capabilities for handling international shipments of drugs and biological specimens involved in clinical trials research.
Buying Marken will help UPS extend that network to a broader array of countries and strengthen its ability to guarantee temperature-controlled, 48-hour delivery of delicate medical samples such as frozen samples of blood, plasma, urine, and tissue, UPS said.
"The two companies are doing different things now, but they're complementary," said John Menna, UPS's vice president of strategy for healthcare logistics, in a phone interview. "Marken has a specialty in clinical trials logistics, and UPS has global capabilities in health care and life sciences in general. Together, we can offer a comprehensive solution end to end."
Marken plans to use the acquisition to leverage UPS' resources and continue to expand its web of clinical supply chain servicesas the pharmaceutical industry reaches out to an increasingly diverse array of countries.
"Finding patients for clinical trials around the world is becoming more difficult and more remote," Marken CEO Wes Wheeler said in an interview. "Drug developers are getting more and more narrow in how they define these patients, particularly around different types of cancer. So we are getting more patients in South America, Asia, and Eastern Europe."
To reach those scattered patients, Marken plans to add to its list of 10 depots, which are supply chain nodes where the company stores drug products and ancillary materials such as centrifuges, needles, syringes, drug leaflets, and laptops, he said. When a new patient is recruited for a drug trial, Marken employees create a tailored package and send it to one of the 45,000 clinics or hospitals where a doctor will administer drug doses and collect samples.
In addition, Marken will invest in its cloud-based inventory control software, called Solo, Wheeler said. The application tracks every dose of an experimental drug as it moves through the supply chain, ensuring that returned or unused drugs are destroyed, so the trial remains compliant with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations.
Wheeler will continue to lead the Marken business after the acquisition, operating it as a wholly owned subsidiary of UPS.
UPS acquires pharmaceutical logistics specialist Marken
Delivery giant continues expansion into lucrative sector of global clinical trials shipments.
By Ben Ames
0 Comments
UPS said the deal is expected to close by Dec. 31.
Atlanta-based UPS has been investing heavily in the specialized services it needs to claim a larger share of this lucrative market. In July, the company announced that it would expand its ability to provide temperature control, precision parcel tracking, and other capabilities for handling international shipments of drugs and biological specimens involved in clinical trials research.
Buying Marken will help UPS extend that network to a broader array of countries and strengthen its ability to guarantee temperature-controlled, 48-hour delivery of delicate medical samples such as frozen samples of blood, plasma, urine, and tissue, UPS said.
"The two companies are doing different things now, but they're complementary," said John Menna, UPS's vice president of strategy for healthcare logistics, in a phone interview. "Marken has a specialty in clinical trials logistics, and UPS has global capabilities in health care and life sciences in general. Together, we can offer a comprehensive solution end to end."
Marken plans to use the acquisition to leverage UPS' resources and continue to expand its web of clinical supply chain servicesas the pharmaceutical industry reaches out to an increasingly diverse array of countries.
"Finding patients for clinical trials around the world is becoming more difficult and more remote," Marken CEO Wes Wheeler said in an interview. "Drug developers are getting more and more narrow in how they define these patients, particularly around different types of cancer. So we are getting more patients in South America, Asia, and Eastern Europe."
To reach those scattered patients, Marken plans to add to its list of 10 depots, which are supply chain nodes where the company stores drug products and ancillary materials such as centrifuges, needles, syringes, drug leaflets, and laptops, he said. When a new patient is recruited for a drug trial, Marken employees create a tailored package and send it to one of the 45,000 clinics or hospitals where a doctor will administer drug doses and collect samples.
In addition, Marken will invest in its cloud-based inventory control software, called Solo, Wheeler said. The application tracks every dose of an experimental drug as it moves through the supply chain, ensuring that returned or unused drugs are destroyed, so the trial remains compliant with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations.
Wheeler will continue to lead the Marken business after the acquisition, operating it as a wholly owned subsidiary of UPS.
Why are you so set?
After a couple failed attempts success has been achieved.
Successful at destroying a company.
Therefore you should be congratulating. You use this real life experience to inspire others.
Once a privately held billion dollar company now set be absorded.
It seems that Wes himself is posting here or at list one of the others morons in North Carolina.
That Marken will continue operating as a subsidiary is only a big lie because the UPS brand is way too big to risk its reputation behind Marken's brand.
Now the big question is; what will happen to us the big mayority down the ladder?
That Marken will continue operating as a subsidiary is only a big lie because the UPS brand is way too big to risk its reputation behind Marken's brand.
Now the big question is; what will happen to us the big mayority down the ladder?
You must really have a man-crush on these guys....you been going on for years....musta been fired due to low sales and people skills....only a fool would keep coming back here to post.